Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Biasi Cavalcanti, Alexandre; G Zampieri, Fernando; Goulart Rosa, Régis; César Pontes Azevedo, Luciano; Cordeiro Veiga, Viviane; Avezum, Álvaro; Petri Damiani, Lucas; Marcadenti, Aline; Kawano-Dourado, Letícia; Lisboa, Thiago; Junqueira, Débora; Gabriel Melo de Barros e Silva, Pedro; Tramujas, Lucas; Oliveira de Abreu Silva, Erlon; Nasi Laranjeira, Lígia; Thomaz Soares, Aline; Santini Echenique, Leandro; José Pereira, Adriano; Geraldo Rezende Freitas, Flávio; Gebara, Otávio; C S Dantas, Vicente; H.M. Furtado, Remo; Pı́polo Milan, Eveline; Alberti Golin, Nicole; Florença Cardoso, Fábio; Silva Maia, Israel; Roberto Hoffmann Filho, Conrado; Kormann, Adrian; Bleuel Amazonas, Roberto; Fernanda Bocchi de Oliveira, Monalisa; Serpa Neto, Ary; Falavigna, Maicon; D. Lópes, Renato; Machado, F.S.; Berwanger, Otávio

doi:10.1056/nejmoa2019014

Public

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Published in New England Journal of Medicine • Jul 23, 2020

Authors:

Alexandre Biasi Cavalcanti

Fernando G Zampieri

Régis Goulart Rosa

Abstract

BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS: We conducted a multicenter, randomized, open-label, three-group, controlled trial involving ...

Subject

Hydroxychloroquine

Azithromycin

Coronavirus disease 2019 (COVID-19)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!